1 Market Overview

1.1 Product Overview and Scope of Alpha 1 Antitrypsin Deficiency Treatment

1.2 Classification of Alpha 1 Antitrypsin Deficiency Treatment by Indication

1.2.1 Overview: Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication: 2017 Versus 2021 Versus 2028

1.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication in 2021

1.2.3 Augmentation Therapy

1.2.4 Cystic Fibrosis(CF)

1.2.5 Non-CF Bronchiectasis(NCFB)

1.2.6 Diabetes

1.2.7 Other

1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market by End Users

1.3.1 Overview: Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users: 2017 Versus 2021 Versus 2028

1.3.2 COPD

1.3.3 Cystic Fibrosis(CF)

1.3.4 Non-CF Bronchiectasis(NCFB)

1.3.5 Diabetes

1.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size & Forecast

1.5 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast by Region

1.5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region, (2017-2022)

1.5.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)

1.5.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)

1.5.6 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers

1.6.2 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints

1.6.3 Alpha 1 Antitrypsin Deficiency Treatment Trends Analysis

2 Company Profiles

2.1 Pfizer

2.1.1 Pfizer Details

2.1.2 Pfizer Major Business

2.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.1.4 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Pfizer Recent Developments and Future Plans

2.2 GlaxoSmithKline

2.2.1 GlaxoSmithKline Details

2.2.2 GlaxoSmithKline Major Business

2.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.2.4 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 GlaxoSmithKline Recent Developments and Future Plans

2.3 AstraZeneca

2.3.1 AstraZeneca Details

2.3.2 AstraZeneca Major Business

2.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.3.4 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 AstraZeneca Recent Developments and Future Plans

2.4 Boehringer Ingelheim

2.4.1 Boehringer Ingelheim Details

2.4.2 Boehringer Ingelheim Major Business

2.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.4.4 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Boehringer Ingelheim Recent Developments and Future Plans

2.5 Teva Pharmaceutical Industries

2.5.1 Teva Pharmaceutical Industries Details

2.5.2 Teva Pharmaceutical Industries Major Business

2.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.5.4 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Teva Pharmaceutical Industries Recent Developments and Future Plans

2.6 Takeda

2.6.1 Takeda Details

2.6.2 Takeda Major Business

2.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.6.4 Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Takeda Recent Developments and Future Plans

2.7 Baxter

2.7.1 Baxter Details

2.7.2 Baxter Major Business

2.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.7.4 Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Baxter Recent Developments and Future Plans

2.8 Grifols

2.8.1 Grifols Details

2.8.2 Grifols Major Business

2.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.8.4 Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Grifols Recent Developments and Future Plans

2.9 CSL Behring

2.9.1 CSL Behring Details

2.9.2 CSL Behring Major Business

2.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.9.4 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 CSL Behring Recent Developments and Future Plans

2.10 Kamada Ltd

2.10.1 Kamada Ltd Details

2.10.2 Kamada Ltd Major Business

2.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.10.4 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Kamada Ltd Recent Developments and Future Plans

2.11 Chiesi Pharmaceuticals

2.11.1 Chiesi Pharmaceuticals Details

2.11.2 Chiesi Pharmaceuticals Major Business

2.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.11.4 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Chiesi Pharmaceuticals Recent Developments and Future Plans

2.12 Kedrion Group

2.12.1 Kedrion Group Details

2.12.2 Kedrion Group Major Business

2.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.12.4 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Kedrion Group Recent Developments and Future Plans

2.13 Vertex Pharmaceuticals

2.13.1 Vertex Pharmaceuticals Details

2.13.2 Vertex Pharmaceuticals Major Business

2.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.13.4 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Vertex Pharmaceuticals Recent Developments and Future Plans

2.14 ProMetic Life Sciences

2.14.1 ProMetic Life Sciences Details

2.14.2 ProMetic Life Sciences Major Business

2.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

2.14.4 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 ProMetic Life Sciences Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share in 2021

3.2.2 Top 10 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Alpha 1 Antitrypsin Deficiency Treatment Players Head Office, Products and Services Provided

3.4 Alpha 1 Antitrypsin Deficiency Treatment Mergers & Acquisitions

3.5 Alpha 1 Antitrypsin Deficiency Treatment New Entrants and Expansion Plans

4 Market Size Segment by Indication

4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by Indication (2017-2022)

4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Indication (2023-2028)

5 Market Size Segment by End Users

5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2017-2022)

5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by End Users (2023-2028)

6 North America by Country, by Indication, and by End Users

6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2028)

6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2028)

6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country

6.3.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2028)

6.3.2 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

6.3.3 Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

6.3.4 Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

7 Europe by Country, by Indication, and by End Users

7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2028)

7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2028)

7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country

7.3.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2028)

7.3.2 Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

7.3.3 France Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

7.3.5 Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

7.3.6 Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Indication, and by End Users

8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2028)

8.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2028)

8.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region

8.3.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (2017-2028)

8.3.2 China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

8.3.3 Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

8.3.4 South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

8.3.5 India Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

8.3.7 Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

9 South America by Country, by Indication, and by End Users

9.1 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2028)

9.2 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2028)

9.3 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country

9.3.1 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2028)

9.3.2 Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

9.3.3 Argentina Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Indication, and by End Users

10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2028)

10.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2028)

10.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country

10.3.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2028)

10.3.2 Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

10.3.4 UAE Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Region (2017-2022)

Table 5. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region (2023-2028)

Table 6. Pfizer Corporate Information, Head Office, and Major Competitors

Table 7. Pfizer Major Business

Table 8. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 9. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors

Table 11. GlaxoSmithKline Major Business

Table 12. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 13. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. AstraZeneca Corporate Information, Head Office, and Major Competitors

Table 15. AstraZeneca Major Business

Table 16. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 17. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors

Table 19. Boehringer Ingelheim Major Business

Table 20. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 21. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Teva Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors

Table 23. Teva Pharmaceutical Industries Major Business

Table 24. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 25. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Takeda Corporate Information, Head Office, and Major Competitors

Table 27. Takeda Major Business

Table 28. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 29. Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Baxter Corporate Information, Head Office, and Major Competitors

Table 31. Baxter Major Business

Table 32. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 33. Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Grifols Corporate Information, Head Office, and Major Competitors

Table 35. Grifols Major Business

Table 36. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 37. Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. CSL Behring Corporate Information, Head Office, and Major Competitors

Table 39. CSL Behring Major Business

Table 40. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 41. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Kamada Ltd Corporate Information, Head Office, and Major Competitors

Table 43. Kamada Ltd Major Business

Table 44. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 45. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Chiesi Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 47. Chiesi Pharmaceuticals Major Business

Table 48. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 49. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Kedrion Group Corporate Information, Head Office, and Major Competitors

Table 51. Kedrion Group Major Business

Table 52. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 53. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Vertex Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 55. Vertex Pharmaceuticals Major Business

Table 56. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 57. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. ProMetic Life Sciences Corporate Information, Head Office, and Major Competitors

Table 59. ProMetic Life Sciences Major Business

Table 60. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions

Table 61. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 63. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 64. Breakdown of Alpha 1 Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2 and Tier 3)

Table 65. Alpha 1 Antitrypsin Deficiency Treatment Players Head Office, Products and Services Provided

Table 66. Alpha 1 Antitrypsin Deficiency Treatment Mergers & Acquisitions in the Past Five Years

Table 67. Alpha 1 Antitrypsin Deficiency Treatment New Entrants and Expansion Plans

Table 68. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Indication (2017-2022)

Table 69. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication (2017-2022)

Table 70. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by Indication (2023-2028)

Table 71. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2022)

Table 72. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by End Users (2023-2028)

Table 73. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2022) & (USD Million)

Table 74. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2023-2028) & (USD Million)

Table 75. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2022) & (USD Million)

Table 76. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2023-2028) & (USD Million)

Table 77. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2022) & (USD Million)

Table 78. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2023-2028) & (USD Million)

Table 79. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2022) & (USD Million)

Table 80. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2023-2028) & (USD Million)

Table 81. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2022) & (USD Million)

Table 82. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2023-2028) & (USD Million)

Table 83. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2022) & (USD Million)

Table 84. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2023-2028) & (USD Million)

Table 85. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2022) & (USD Million)

Table 86. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2023-2028) & (USD Million)

Table 87. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2022) & (USD Million)

Table 88. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2023-2028) & (USD Million)

Table 89. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (2017-2022) & (USD Million)

Table 90. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (2023-2028) & (USD Million)

Table 91. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2022) & (USD Million)

Table 92. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2023-2028) & (USD Million)

Table 93. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2022) & (USD Million)

Table 94. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2023-2028) & (USD Million)

Table 95. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2022) & (USD Million)

Table 96. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2023-2028) & (USD Million)

Table 97. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2022) & (USD Million)

Table 98. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2023-2028) & (USD Million)

Table 99. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2022) & (USD Million)

Table 100. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2023-2028) & (USD Million)

Table 101. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2022) & (USD Million)

Table 102. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Alpha 1 Antitrypsin Deficiency Treatment Picture

Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication in 2021

Figure 3. Augmentation Therapy

Figure 4. Cystic Fibrosis(CF)

Figure 5. Non-CF Bronchiectasis(NCFB)

Figure 6. Diabetes

Figure 7. Other

Figure 8. Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users in 2021

Figure 9. COPD Picture

Figure 10. Cystic Fibrosis(CF) Picture

Figure 11. Non-CF Bronchiectasis(NCFB) Picture

Figure 12. Diabetes Picture

Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 14. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Forecast (2017-2028) & (USD Million)

Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region (2017-2028)

Figure 16. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region in 2021

Figure 17. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 21. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 22. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers

Figure 23. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints

Figure 24. Alpha 1 Antitrypsin Deficiency Treatment Market Trends

Figure 25. Pfizer Recent Developments and Future Plans

Figure 26. GlaxoSmithKline Recent Developments and Future Plans

Figure 27. AstraZeneca Recent Developments and Future Plans

Figure 28. Boehringer Ingelheim Recent Developments and Future Plans

Figure 29. Teva Pharmaceutical Industries Recent Developments and Future Plans

Figure 30. Takeda Recent Developments and Future Plans

Figure 31. Baxter Recent Developments and Future Plans

Figure 32. Grifols Recent Developments and Future Plans

Figure 33. CSL Behring Recent Developments and Future Plans

Figure 34. Kamada Ltd Recent Developments and Future Plans

Figure 35. Chiesi Pharmaceuticals Recent Developments and Future Plans

Figure 36. Kedrion Group Recent Developments and Future Plans

Figure 37. Vertex Pharmaceuticals Recent Developments and Future Plans

Figure 38. ProMetic Life Sciences Recent Developments and Future Plans

Figure 39. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players in 2021

Figure 40. Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 41. Global Top 3 Players Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share in 2021

Figure 42. Global Top 10 Players Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share in 2021

Figure 43. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 44. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication in 2021

Figure 45. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Indication (2023-2028)

Figure 46. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users in 2021

Figure 47. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by End Users (2023-2028)

Figure 48. North America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Indication (2017-2028)

Figure 49. North America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End Users (2017-2028)

Figure 50. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2017-2028)

Figure 51. United States Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Canada Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Mexico Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Indication (2017-2028)

Figure 55. Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End Users (2017-2028)

Figure 56. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2017-2028)

Figure 57. Germany Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. France Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Russia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Italy Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Indication (2017-2028)

Figure 63. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End Users (2017-2028)

Figure 64. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region (2017-2028)

Figure 65. China Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. Japan Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. South Korea Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. India Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Australia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. South America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Indication (2017-2028)

Figure 72. South America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End Users (2017-2028)

Figure 73. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2017-2028)

Figure 74. Brazil Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Argentina Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Indication (2017-2028)

Figure 77. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End Users (2017-2028)

Figure 78. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2017-2028)

Figure 79. Turkey Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. UAE Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 82. Methodology

Figure 83. Research Process and Data Source